FILING ANALYSIS · MONDAY, NOVEMBER 9
OCULAR THERAPEUTIX, INC OCUL — 8-K: Results of Operations and Financial Condition
neutral
Ocular Therapeutix reported a cash balance of $530.6 million as of September 30, 2026, and is on track to submit its NDA for AXPAXLI in wet AMD in the fourth quarter, with a strong commercial readiness plan in place.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →